ROSIPTOR
Bladder Pain Syndrome
Aquinox Pharmaceuticals (Canada) Inc.Small moleculePhase 3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Bladder Pain Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Doxycycline Insel Gruppe AG, University Hospital Bern | Phase 4 | B |
Triamcinalone Jocelyn Fitzgerald | Phase 3 | B |
Amitriptyline Jocelyn Fitzgerald | Phase 3 | B |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Jocelyn Fitzgerald | Phase 3 | B |
HEPARIN Jocelyn Fitzgerald | Phase 3 | B |
View all 17 →
Same molecule, other indications
ROSIPTOR is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →